Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831

PURPOSE: To assess whether trastuzumab (H) with radiotherapy (RT) increases adverse events (AEs) after breast-conserving surgery or mastectomy. PATIENTS AND METHODS: Patients with early-stage resected human epidermal growth factor receptor 2 (HER-2) –positive breast cancer (BC) were randomly assigne...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Halyard, Michele Y., Pisansky, Thomas M., Dueck, Amylou C., Suman, Vera, Pierce, Lori, Solin, Larry, Marks, Larry, Davidson, Nancy, Martino, Silvana, Kaufman, Peter, Kutteh, Leila, Dakhil, Shaker R., Perez, Edith A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2690390/
https://ncbi.nlm.nih.gov/pubmed/19349549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.9549
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados